Skip to content

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07599241
Enrollment
40
Registered
2026-05-20
Start date
2026-03-15
Completion date
2026-12-15
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma, Subclinical hypothyroïdism

Brief summary

additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated

Detailed description

hypthyroidism elder females (n=40) with glaucoma and fatty liver issues will randomly divided into group number 1 (n=20) that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month or group number II (n=20) that will receive levothyroxine only

Interventions

BEHAVIORALphysical activity

hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month

OTHERusual care

hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
65 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* subclinical hypothrodism (significant form) * primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma) * fatty liver (non alcholic type) * elder females

Exclusion criteria

* respiratory issues * cardiac issues * renal issues

Design outcomes

Primary

MeasureTime frameDescription
intraocular pressure6 monthsit will be assessed in both eyes

Secondary

MeasureTime frameDescription
body mass index6 monthsit will be assessed on empty stomach and bladder
waist circumfrence6 monthsit will be assessed by tape at umblical level
systolic blood pressure6 monthsit will be assessed by sphygmomanmometer
diastolic blood pressure6 monthsit will be assessed by sphygmomanmometer
glaucoma assocaited life quality survey6 monthsit is a questionaire evaluates life quality
triglyceridss6 monthsit will be assessed in serum
high density lipoproteines6 monthsit will be assesed in serum
alanine transamianses6 monthsit will be assessed in serum
aspartate trasnamiansses6 monthsit will be assessed in serum
physical conclusion of short form survey6 monthsit will assess physical quality of lifes of females
Mental conclusion of short form survey6 monthsit will assess physical quality of lifes of females
thyroid stimualting horomone6 monthsit will be assessed in serum
fasting glycemia value6 monthsit will be assessed in serum

Countries

Egypt

Contacts

CONTACTAli MA Ismail, lecturer
ali.mohamed@pt.cu.edu.eg01005154209
CONTACTfatma M Ali
fatma1995@gmail.com01031321109
PRINCIPAL_INVESTIGATORAli MA Ismail, lecturer

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026